Dyslipidemia

At the NLA Scientific Sessions in Las Vegas this morning, Akcea Therapeutics, presented a poster with data from the largest burden of illness study in patients with FCS to date.

At the NLA Scientific Sessions in Las Vegas, NV this weekend, Akcea Therapeutics will present clinical data on volanesorsen and FCS.

Patients who consumed vinegar daily along with a restricted calorie diet lost more weight and saw improved BMI scores compared to those just on the diet.

Black patients had a 62% greater chance of having experienced an ischemic stroke pre-AF diagnosis, and a 67% higher risk of having one post-AF diagnosis.

Akcea announced that the Division of Metabolism and Endocrinology Products of the U.S. FDA will hold an advisory committee meeting to review data supporting the NDA for volanesorsen.

Depressed elderly patients undergoing SAVR or TAVR had a 7.3% higher rate of mortality compared to non-depressed patients.

Varenicline (Chantix) increases patients’ risk of an emergency department visit or hospitalization for a cardiovascular event by 34%.

Kevin Maki, PhD, discussed the impact that the new guidelines for hypertension from the AHA and the ACC will have on patients and physicians.

Renova Therapeutics is planning a 536-patient phase 3 trial, FLOURISH, to begin in early 2018.

Kevin Maki, PhD, discussed the current state of lipid care in the United States.

OZEMPIC, a GLP-1 receptor agonist, was tested in 2-year cardiovascular outcome trials.

The smart strap is the first medical accessory for a smartwatch to receive FDA approval.